Ironwood, AbbVie win U.S. label expansion for Linzess in pediatric constipation
Source: SeekingAlpha
2026-05-27 11:00:30 ET
More on Ironwood Pharmaceuticals, AbbVie
- Ironwood Pharmaceuticals: A Contrarian Buy Opportunity
- Ironwood Pharmaceuticals: Still A Profitable Opportunity
- AbbVie Inc. (ABBV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
- Small-cap healthcare stocks ranked by quant ratings after earnings season
- AbbVie, Merck, Astra among winners of EU drug recommendations this week
Read the full article on Seeking Alpha
For further details see:
Ironwood, AbbVie win U.S. label expansion for Linzess in pediatric constipation
Ironwood Pharmaceuticals Inc.
NASDAQ: IRWD
IRWD Trading
7.2% G/L:
$3.425 Last:
1,085,427 Volume:
$3.25 Open:
IRWD Latest News
IRWD Stock Data
$754,015,529
142,018,459
0.3%
66
N/A
Pharmaceuticals
Healthcare
US
Boston
